The biologics license application from the FDA is supported by data from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan in HR-positive, HER2-negative breast cancer.
The FDA accepted the BLA of Dato-DXd, a TROP2-directed antibody-drug conjugate, in patients with HR+, HER2– breast cancer that has been previously treated with systemic therapy. A PDUFA target action date has been set for the first quarter of 2025.1
The BLA is supported by findings from the phase 3 TROPION-Breast01 trial (NCT05104866). According to data presented at the 2023 European Society of Medical Oncology Annual Congress, Dato-DXd reduced the risk of disease progression or death by 37% compared with investigator’s choice of chemotherapy (HR, 0.63; 95% CI, 0.52-0.76; P <.001) as assessed by blinded independent central review. The confirmed objective response rates (ORR) were 36.4% and 22.9% for Dato-DXd and chemotherapy, respectively.2
Progression-free survival (PFS) findings were presented at the 2023 San Antonio Breast Cancer Symposium. A median PFS of 6.9 months was observed in patients treated with Dato-DXd (n = 365) vs 4.9 months in patients who received chemotherapy (n = 367; HR, 0.63; 95% CI, 0.52-0.76; P <.0001).3
“Despite marked progress in the treatment of HR-positive, HER2-negative breast cancer, most patients with advanced disease develop endocrine resistance and face the prospect of one or several lines of chemotherapy. If approved, datopotamab deruxtecan has the potential to provide these patients an efficacious and better tolerated alternative to conventional chemotherapy,” said Susan Galbraith, executive vice president of oncology research and development at AstraZeneca, in a press release.1
In February 2024, the FDA accepted a BLA for Dato-DXd for the treatment of nonsquamous NSCLC, and a PDUFA target action date is anticipated in the fourth quarter of 2024.4
TROPION-Breast01 is a phase 3, open-label, randomized study of Dato-DXd vs investigator’s choice of chemotherapy in patients with inoperable or metastatic HR+, HER2– breast cancer who have received 1 or 2 prior lines of systemic therapy. The study has an enrollment of 732 patients across sites in 10 states in the US and 19 additional countries.5
The study’s primary end points are PFS and overall survival, and secondary end points include ORR, duration of response, PFS by investigator assessment, disease control rate, time to first subsequent therapy, and time to second subsequent therapy.
The study is active but not recruiting and has an estimated completion date of August 15, 2025.
FDA Accepts sBLA of Dostarlimab/Chemo to Include All Advanced Endometrial Cancer
April 24th 2024The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a Prescription Drug User Fee Act action date of August 23, 2024.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More